Share
array:22 [ "pii" => "S2445146022000917" "issn" => "24451460" "doi" => "10.1016/j.vacune.2022.10.022" "estado" => "S300" "fechaPublicacion" => "2022-09-01" "aid" => "242" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2022;23 Supl 2:S123-S124" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S2445146022000929" "issn" => "24451460" "doi" => "10.1016/j.vacune.2022.10.023" "estado" => "S300" "fechaPublicacion" => "2022-09-01" "aid" => "236" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2022;23 Supl 2:S125-S126" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the editor</span>" "titulo" => "Lack of COVID-19 vaccination in rural areas of Pakistan" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S125" "paginaFinal" => "S126" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Falta de la vacuna frente a la COVID-19 en zonas rurales de Pakistán" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alisha Saleem, Maha Rashid, Ameerah Shaikh, Sajjad Ali" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Alisha" "apellidos" => "Saleem" ] 1 => array:2 [ "nombre" => "Maha" "apellidos" => "Rashid" ] 2 => array:2 [ "nombre" => "Ameerah" "apellidos" => "Shaikh" ] 3 => array:2 [ "nombre" => "Sajjad" "apellidos" => "Ali" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146022000929?idApp=UINPBA00004N" "url" => "/24451460/00000023000000S2/v3_202404040650/S2445146022000929/v3_202404040650/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S2445146022000905" "issn" => "24451460" "doi" => "10.1016/j.vacune.2022.10.021" "estado" => "S300" "fechaPublicacion" => "2022-09-01" "aid" => "246" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2022;23 Supl 2:S121-S122" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the editor</span>" "titulo" => "Recommendation of a fourth SARS-CoV-2 vaccine dosage in vulnerable individuals, yes or not?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S121" "paginaFinal" => "S122" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Recomendación de una cuarta dosis de vacuna frente a SARS-CoV-2 en individuos vulnerables: ¿sí o no?" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Masoud Keikha" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Masoud" "apellidos" => "Keikha" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146022000905?idApp=UINPBA00004N" "url" => "/24451460/00000023000000S2/v3_202404040650/S2445146022000905/v3_202404040650/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the editor</span>" "titulo" => "Early diagnosis and treatment of SARS-CoV-2 vaccination associated polyradiculitis improves outcome" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S123" "paginaFinal" => "S124" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Josef Finsterer, Fulvio A. Scorza" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Josef" "apellidos" => "Finsterer" "email" => array:1 [ 0 => "fifigs1@yahoo.de" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "af0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cr0005" ] ] ] 1 => array:4 [ "nombre" => "Fulvio A." "apellidos" => "Scorza" "email" => array:1 [ 0 => "scorza@unifesp.br" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "af0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Neurology & Neurophysiology Center, Vienna, Austria" "etiqueta" => "a" "identificador" => "af0005" ] 1 => array:3 [ "entidad" => "Disciplina de Neurociência, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM), São Paulo, Brazil" "etiqueta" => "b" "identificador" => "af0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cr0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author at: Postfach 20, 1180 Vienna, Austria" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "El diagnóstico y el tratamiento precoz y de la polirradiculitis asociada a la vacuna frente al SARS-CoV-2 mejora el resultado" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="p0005" class="elsevierStylePara elsevierViewall">We read with interest the article by Sosa-Hernández and Sánchez-Cardoza about a 23 years old male who developed quadruparesis (M3) one day after the second dose of the BNT162b2 vaccine (BNV) resulting in the inability to walk or accomplish daily activities.<a class="elsevierStyleCrossRef" href="#bb0005"><span class="elsevierStyleSup">1</span></a> His previous history was positive for glomerulonephritis, hypothyroidism, arterial hypertension, surgery for atrial septal defect, and multiple allergies.<a class="elsevierStyleCrossRef" href="#bb0005"><span class="elsevierStyleSup">1</span></a> His current medication included mycophenolate mofetil, tacrolimus, L-thyroxine, losartan, and spironolactone.<a class="elsevierStyleCrossRef" href="#bb0005"><span class="elsevierStyleSup">1</span></a> The patient was diagnosed with acute, inflammatory demyelinating polyneuropathy (AIDP), treated with intravenous immunoglobulins (IVIG) and steroids, and made a partial recovery.<a class="elsevierStyleCrossRef" href="#bb0005"><span class="elsevierStyleSup">1</span></a> The study is attractive but raises concerns that should be discussed.</p><p id="p0010" class="elsevierStylePara elsevierViewall">Diagnosing Guillain-Barre syndrome (GBS) according to the Brighton criteria requires not only a clinical exam, nerve conduction studies (NCSs) but also investigations of the cerebrospinal fluid (CSF). We should be told why the patient did not undergo CSF investigations to confirm dissociation between CSF protein and CSF cell count and to exclude differential diagnoses.</p><p id="p0015" class="elsevierStylePara elsevierViewall">We should be told why NCSs were carried out not earlier than three weeks after onset of quadruparesis. Diagnosing GBS early is a prerequisite for a favourable outcome.<a class="elsevierStyleCrossRef" href="#bb0010"><span class="elsevierStyleSup">2</span></a> If the diagnosis is delayed the outcome is usually worse than when the treatment is started early.<a class="elsevierStyleCrossRef" href="#bb0010"><span class="elsevierStyleSup">2</span></a></p><p id="p0020" class="elsevierStylePara elsevierViewall">The outcome of GBS patients also depends on the type of treatment applied. Patients receiving steroids usually have a worse outcome as compared those receiving intravenous immunoglobulins (IVIGs) plasma exchange (PE).<a class="elsevierStyleCrossRef" href="#bb0015"><span class="elsevierStyleSup">3</span></a> We should be told why the index patient received steroids in addition to IVIG. The combination of both remedies does not improve the overall outcome.</p><p id="p0025" class="elsevierStylePara elsevierViewall">We disagree that GBS is a rare complication of anti-SARS-CoV-2 vaccinations.<a class="elsevierStyleCrossRef" href="#bb0005"><span class="elsevierStyleSup">1</span></a> In a recent review about the neurological side effects of anti-SARS-CoV-2 vaccination more than 300 cases with anti-SARS-CoV-2 vaccination associated GBS had been reported as per the end of September 2021.<a class="elsevierStyleCrossRef" href="#bb0020"><span class="elsevierStyleSup">4</span></a></p><p id="p0030" class="elsevierStylePara elsevierViewall">One reason why the prevalence of GBS did not increase since the introduction of anti-SARS-CoV-2 vaccines is that GBS is an overarching term for a number of subtypes that might be easily missed or misdiagnosed. Particularly, if GBS manifests as mono- or poly-neuritis cranialis and without involvement of the peripheral nerves, the clinical presentation may be easily misdiagnosed without considering a subtype of GBS. If these subtypes of GBS are missed or misinterpreted, the prevalence of SARS-CoV-2 vaccination associated GBS may remain low.</p><p id="p0035" class="elsevierStylePara elsevierViewall">We disagree with the statement in the abstract that GBS affects only peripheral nerves. There is a subtype of GBS known as Bickerstaff encephalitis, which goes along with brainstem encephalitis.<a class="elsevierStyleCrossRef" href="#bb0025"><span class="elsevierStyleSup">5</span></a></p><p id="p0040" class="elsevierStylePara elsevierViewall">It is unclear if the patient was on the immune-suppressive medication for glomerulonephritis at the time of the vaccination. If he was taking mycophenolate and tacrolimus at the time of the second BPV application, it should be discussed to which degree immunosuppression favoured the development GBS.</p><p id="p0045" class="elsevierStylePara elsevierViewall">Overall, the interesting study has some limitations and inconsistencies that call the results and their interpretation into question. Addressing these limitations could further strengthen and reinforce the statement of the study. Anti-SARS-CoV-2 vaccination associated GBS is not rare and should be diagnosed early not to miss the chance for early treatment which can improve the outcome of these patients.</p><span id="s0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0010">Funding sources</span><p id="p0050" class="elsevierStylePara elsevierViewall">No funding was received.</p></span><span id="s0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0015">Conflicts of interest</span><p id="p0055" class="elsevierStylePara elsevierViewall">The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.'</p></span><span id="s0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0020">Availability of data</span><p id="p0060" class="elsevierStylePara elsevierViewall">All data are available from the corresponding author.</p></span><span id="s0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0025">Author contribution</span><p id="p0065" class="elsevierStylePara elsevierViewall">JF: design, literature search, discussion, first draft, critical comments, final approval.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:6 [ 0 => array:2 [ "identificador" => "xpalclavsec1804125" "titulo" => "Abbreviations" ] 1 => array:2 [ "identificador" => "s0005" "titulo" => "Funding sources" ] 2 => array:2 [ "identificador" => "s0010" "titulo" => "Conflicts of interest" ] 3 => array:2 [ "identificador" => "s0015" "titulo" => "Availability of data" ] 4 => array:2 [ "identificador" => "s0020" "titulo" => "Author contribution" ] 5 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "abr" "titulo" => "Abbreviations" "identificador" => "xpalclavsec1804125" "palabras" => array:6 [ 0 => "BNV" 1 => "CSF" 2 => "GBS" 3 => "IVIG" 4 => "NCSs" 5 => "PE" ] ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bb0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reporte de caso de síndrome de Guillain-Barré posterior a la vacuna COVID BNT162b2 mRNA [Case report of Guillain-Barré Syndrome after COVID BNT162b2 mRNA vaccine]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "O. Sosa-Hernández" 1 => "S. Sánchez-Cardoza" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vacun.2022.02.002" "Revista" => array:2 [ "tituloSerie" => "Vacunas." "fecha" => "2022 May 2" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bb0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guillain-Barré syndrome in children: subtypes and outcome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Z.S. Karalok" 1 => "B.D. Taskin" 2 => "Z.B. Yanginlar" 3 => "E. Gurkas" 4 => "A. Guven" 5 => "A. Degerliyurt" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00381-018-3856-0" "Revista" => array:7 [ "tituloSerie" => "Childs Nerv Syst" "fecha" => "2018 Nov" "volumen" => "34" "numero" => "11" "paginaInicial" => "2291" "paginaFinal" => "2297" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29948140" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bb0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of therapies in the treatment of Guillain-Barre syndrome: A network meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Lin" 1 => "Q. Gao" 2 => "K. Xiao" 3 => "D. Tian" 4 => "W. Hu" 5 => "Z. Han" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MD.0000000000027351" "Revista" => array:4 [ "tituloSerie" => "Medicine (Baltimore)" "fecha" => "2021 Oct 15" "volumen" => "100" "numero" => "41" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bb0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neurological side effects of SARS-CoV-2 vaccinations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Finsterer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ane.13550" "Revista" => array:7 [ "tituloSerie" => "Acta Neurol Scand" "fecha" => "2022 Jan" "volumen" => "145" "numero" => "1" "paginaInicial" => "5" "paginaFinal" => "9" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34750810" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bb0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bickerstaff encephalitis after COVID-19" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "L. Llorente Ayuso" 1 => "P. Torres Rubio" 2 => "R.F. Beijinho do Rosário" 3 => "M.L. Giganto Arroyo" 4 => "F. Sierra-Hidalgo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00415-020-10201-1" "Revista" => array:7 [ "tituloSerie" => "J Neurol" "fecha" => "2021 Jun" "volumen" => "268" "numero" => "6" "paginaInicial" => "2035" "paginaFinal" => "2037" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32880723" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:2 [ "identificador" => "xack737275" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/24451460/00000023000000S2/v3_202404040650/S2445146022000917/v3_202404040650/en/main.assets" "Apartado" => array:4 [ "identificador" => "66708" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Special Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/24451460/00000023000000S2/v3_202404040650/S2445146022000917/v3_202404040650/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146022000917?idApp=UINPBA00004N" ]
